RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Raises Price Target to $18
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and raises the price target from $17 to $18.
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and raises the price target from $17 to $18.